vivabioscience产品代理
vivabioscience产品代理
截至2021年6月30日，非凡生物已为全球1695家生物技术和制药客户提供药物研发和生产服务。我们总共投资和孵化了75家生物科技初创企业。未来，公司将继续加强技术壁垒，提高研发生产水平和服务能力，为更多的药物发现初创企业以及世界各地的大中型医药企业提供优质、多元化的服务。
Cell Lines
Crystal Structures
GPCR Proteins
Antibody
Protein
Since its establishment in 2008, Viva Biotech (01873.HK) has always been adhering to the mission of "Becoming the cradle of global innovative biotech companies from around the world" and provided one-stop services for drug R&D and production to global biopharmaceutical innovators. Leveraging the technical advantages in the field of Structure-based Drug Discovery (SBDD), we provide leading CRO drug discovery services and CMC / CDMO services throughout the whole drug production process to global biopharmaceutical clients. At the same time, we focus on finding and investing in high potential biotech start-ups, solve unmet clinical medical needs in the form of EFS (service for equity), and continue to build an open cooperation platform and win-win ecosystem for biotech innovation.
As of June 30, 2021, Viva Biotech has provided drug R&D and production services to 1,695 biotech and pharmaceutical clients around the world. We have invested and incubated 75 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva’s platform.
